terbinafine has been researched along with Mycoses* in 5 studies
1 review(s) available for terbinafine and Mycoses
Article | Year |
---|---|
The biology and chemistry of antifungal agents: a review.
In recent years their has been an increased use of antifungal agents and has resulted in the development of resistance to drugs. Currently, use of standard antifungal therapies can be limited because of toxicity, low efficacy rates. Different types of mechanisms contribute to the development of resistance to antifungals. This has given raise to search for a new heterocycle with distinct action or multitargeted combination therapy. This review addresses the areas such as the underlying mechanisms, eight different targets such as ergosterol synthesis, chitin synthesis, ergosterol disruptors, glucan synthesis, squalene epoxidase, nucleic acid synthesis, protein synthesis, microtubules synthesis. The clinically employed drugs along with the current research work going on worldwide on different heterocycles are discussed. In recent advances various heterocycles including imidazole, benzimidazole etc., twenty three scaffolds and their lead identification are discussed. Topics: Animals; Antifungal Agents; Azoles; Fungi; Humans; Imidazoles; Mycoses | 2012 |
4 other study(ies) available for terbinafine and Mycoses
Article | Year |
---|---|
Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
Due to the increased morbidity and mortality by fungal infections and the emergence of severe antifungal resistance, there is an urgent need for new antifungal agents. Here, we screened for antifungal activity in our in-house library through the minimum inhibitory concentration test and derived two hit compounds with moderate antifungal activities. The hit compounds' antifungal activities and drug-like properties were optimized by substituting various aryl ring, alkyl chain, and methyl groups. Among the optimized compounds, Topics: Animals; Antifungal Agents; Cell Wall; Drug Evaluation, Preclinical; Drug Synergism; Female; Fungi; Humans; Male; Mice; Microbial Sensitivity Tests; Mycoses; Rats, Sprague-Dawley | 2021 |
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
A series of 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols (1a-v, 2a-w), which are analogues of fluconazole, have been designed and synthesized as the potential antifungal agents by the click reaction. Click reaction approach toward the synthesis of two sets of novel 1,2,3-triazolyl linked triazole antifungal derivatives 1a-v, 2a-w was achieved by Cu(I)-catalyzed 1,3-dipolar cycloaddition of propargylated intermediate 8 with substituted azidomethyl benzene. The 1,2,3-triazolyl group was inserted into the side chain of the target molecule which can increase the antifungal activity of compounds. Topics: 14-alpha Demethylase Inhibitors; Antifungal Agents; Fungi; Humans; Models, Molecular; Mycoses; Sterol 14-Demethylase; Triazoles | 2010 |
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
A microdilution method was used to test 11 antifungal drugs against clinical isolates of Fusarium thapsinum and three different phylogenetic clades of Fusarium verticillioides that were characterized by sequencing a region of the beta-tubulin gene. Terbinafine was the most-active drug against both species, followed by posaconazole against F. verticillioides. Topics: Animals; Antifungal Agents; Drug Resistance, Fungal; Fusarium; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mycoses; Naphthalenes; Sequence Analysis, DNA; Terbinafine; Triazoles; Tubulin | 2008 |
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
In search for new compounds with potential for clinical use as antifungal agents in dermatology, a series of 12 azole compounds were synthesized stereospecifically and investigated specifically for their activity against dermatophyte fungal infections in animal models. This panel of azoles was studied in vitro and compared with itraconazole and terbinafine for their antifungal activity using a panel of 24 Candida spp. and 182 dermatophyte isolates. Three azoles (1c, 2c, and 4c) showed in vitro antifungal potency equivalent to itraconazole, but superior to terbinafine, against a panel of 24 Candida spp. with comparable or lower activity than that of itraconazole and terbinafine against 182 dermatophyte isolates and only rare activity against other pathogenic fungi. However, in vivo 1c and 4c, both given orally, demonstrated antifungal activity at least three times greater than itraconazole and were superior compared to terbinafine in M. canis infected guinea pigs. In a mouse model infected by T. mentagrophytes, again 4c, but not 1c, showed 5-fold superior activity over itraconazole and terbinafine. Compound 2c was effective in both models but less effective than itraconazole in these models. On the basis of these promising results, 4c is currently being clinically investigated for its potential as a novel antifungal agent against dermatophytosis. Topics: Animals; Antifungal Agents; Dermatologic Agents; Guinea Pigs; Imidazoles; Itraconazole; Mice; Mitosporic Fungi; Mycoses; Naphthalenes; Stereoisomerism; Structure-Activity Relationship; Terbinafine; Triazoles | 2005 |